This video is sponsored by the Duke Clinical Medical Series.
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
Rick Nishimura, MD has indicated that his presentation does not include discussion of any
off-label, experimental, and/or investigational uses of drugs or devices. Frederick Meine,
MD has indicated that the use of Beta-blockers for HOCM is an off-label, experimental,
and/or investigational use of drugs.
|
|